Please assess the completion status of the following clinical trial:

Trial Title: Trial of Drain Antisepsis After Tissue Expander Breast Reconstruction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females or males age 18-90 able to give informed consent~* Undergoing bilateral mastectomy with immediate expander reconstruction or immediate implant reconstruction~* May have either malignant or benign breast condition~Exclusion Criteria:~* Antibiotic use in the fourteen days prior to surgical date~* Undergoing unilateral tissue expander reconstruction~* Documented allergy to chlorhexidine gluconate~* Prior radiation therapy to the breast or chest wall (ie for breast conservation or mantle radiation for Hodgkin's disease)~* Documented allergy to all three of the following antibiotics: cephalosporin, trimethoprim/sulfamethoxazole, and levofloxacin~* Pregnant women~* Vulnerable subjects - prisoners, institutionalized individuals~* Non-English speaking patients without adequate interpreter assistance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Antisepsis Side (Type: EXPERIMENTAL): A chlorhexidine gluconate disk (BioPatch) covered by an occlusive adhesive dressing (Tegaderm) will be applied to the intervention drain sites and changed every three days. The drainage bulb will be irrigated with 10ml of 0.125% sodium hypochlorite (Dakin's solution) twice a day.
- Control Side (Type: OTHER): Standard drain care will be performed twice a day or three times if bulb is full and needs to be emptied. Standard drain care consists of stripping the tubing, emptying the drainage bulb, recording the volume of fluid, and cleaning the drain site with a cotton swab dipped in rubbing alcohol. The drain exit will be covered with a dry sterile gauze dressing and changed after each episode of drain care.

Based on this trial design, predict the completion outcome and termination type (if applicable).